Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies

Trial Profile

Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2019

At a glance

  • Drugs Omidubicel (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Sponsors Gamida-Cell
  • Most Recent Events

    • 31 May 2019 According to a Gamida Cell media release, summary of clinical and translational data (two presentations) from this study were presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting (ISCT 2019).
    • 31 May 2019 Results (summary of clinical and translational data) from this phase 1/2 study in patients with high-risk hematologic malignancies, or blood cancers presented in a Gamida Cell media release.
    • 02 Jan 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top